Bls 1 frá 17 niðurstöður
FIELD OF THE INVENTION
This invention relates to the preparation of phosphatase inhibitors that act as phosphotyrosine mimetics. The invention particularly relates to compounds designed to inhibit protein-tyrosine phosphatase 1B, and for the treatment of diabetes.
SUMMARY OF THE RELATED ART
Protein
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the preparation of phosphatase inhibitors that act as phosphotyrosine mimetics. The invention particularly relates to compounds designed to inhibit protein-tyrosine phosphatase 1B, and for the treatment of diabetes.
2.
FIELD OF THE INVENTION
This invention is in the field of biological medicine and specifically relates to the preparation, pharmacological activities and application of twelve bromophenol compounds, including: (2'-bromo-6'-(dibromomethyl)-3',4'-dimethoxyphenyl)-(2,3-dibromo-4,5-dime-
FIELD OF THE INVENTION
The present invention comprises small molecular weight, non-peptidic inhibitors of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
BACKGROUND OF THE INVENTION
The mechanism of
The present invention comprises small molecular weight, non-peptidic inhibitors of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
BACKGROUND OF THE INVENTION
The mechanism of insulin action depends
BACKGROUND
The present disclosure relates generally to compounds that inhibit protein tyrosine phosphatases (PTPs). PTPs play an important role in the regulation of cellular growth and differentiation by serving as key regulatory components in the tyrosine phosphorylation-mediated signaling
FIELD OF THE INVENTION
The present invention relates to novel thienopyridines, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
TECHNICAL FIELD
The present invention relates to methods for using human placental alkaline phosphatase, an enzyme produced by human placenta during pregnancy, to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of
TECHNICAL FIELD
The present invention relates to methods for using human placental alkaline phosphatase, an enzyme produced by human placenta during pregnancy, to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of
TECHNICAL FIELD
The present invention relates to methods for using human placental alkaline phosphatase, an enzyme produced by human placenta during pregnancy, to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of
TECHNICAL FIELD
The present invention relates to methods for using human placental alkaline phosphatase, an enzyme produced by human placenta during pregnancy, to reduce blood glucose level in a mammal. Treatment regimens provided by the invention maybe used to control Type 1 and Type 2 forms of
This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their
FIELD OF THE INVENTION
The present invention relates to the use of purified limonoin glucoside for the treatment of chronic inflammatory diseases.
BACKGROUND OF THE INVENTION
Circulating concentrations of the hepatic enzymes gamma glutamyl transferase (GGT), alanine amino transferase (ALT), alkaline